Taxanes for adjuvant treatment of early breast cancer
Sübutlu məlumatların xülasələri
14.07.2017 • Sonuncu dəyişiklik 14.07.2017
Editors
Taxanes are effective as adjuvant chemotherapy regimens for improving overall and disease-free survival for women with operable early breast cancer compared to non-taxane regimens.
A Cochrane review included 12 studies involving a total of 21 191 women. The weighted average median follow up was 60.4 months. The HR for overall survival was 0.81 (95% CI 0.75 to 0.88, P < 0.00001, 2 483 deaths amongst 18 304 women) favouring taxane (paclitaxel or docetaxel) containing regimens. The HR for disease-free survival was 0.81 (95% CI 0.77 to 0.86, P < 0.00001, 4 800 events in 19 943 women) favouring taxane containing regimens. There was no statistical heterogeneity.
Ədəbiyyat
- Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007 Oct 17;(4):CD004421.